Why the study?
Improvement of conventional secondary risk factors is unlikely to explain the prognostic benefits of SGLT2i in heart failure, leaving their underlying mechanisms of action incompletely understood.
SGLT2 inhibitors provide prognostic benefits in heart failure through pleiotropic mechanisms beyond conventional risk factor modification, supporting their use in HFrEF and potentially HFpEF.
Answers are grounded in this paper and cite their sources.
Provides mechanistic rationale for SGLT2 inhibitor use in HF; leaves open dominant pathways for targeted validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Pabel et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: